Tandem Diabetes Care
TNDM
379 hedge funds and large institutions have $6.84B invested in Tandem Diabetes Care in 2022 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 153 increasing their positions, 119 reducing their positions, and 66 closing their positions.
124% more call options, than puts
Call options by funds: $55.9M | Put options by funds: $24.9M
29% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 119
6% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 66
1.92% less ownership
Funds ownership: 95.11% → 93.2% (-1.9%)
2% less funds holding
Funds holding: 388 → 379 (-9)
25% less capital invested
Capital invested by funds: $9.07B → $6.84B (-$2.23B)
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$58M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$56.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$51M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$31.7M |
| 5 |
Millennium Management
New York
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$117M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$67.8M |
| 3 |
Jennison Associates
New York
|
-$41.8M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$36.4M |
| 5 |
Morgan Stanley
New York
|
-$35.4M |
TNDM Hedge Fund Activity: Q1 2022 in Review
379 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q1 2022, worth a combined $6.84B — down 25% from $9.07B a quarter earlier.
Sellers outnumbered buyers: 66 funds closed out of TNDM and 62 opened new positions — a net loss of 4 holders — while 119 trimmed existing stakes and 153 added.
The largest buyer was Fidelity Investments, adding an estimated $58M. The largest seller was Jackson Square Partners, cutting an estimated $117M.
- 379 institutional investors held Tandem Diabetes Care (TNDM) as of Q1 2022, down from 388 in Q4 2021.
- Funds reported $6.84B of Tandem Diabetes Care stock for Q1 2022, down 25% quarter-over-quarter.
- 62 funds opened new Tandem Diabetes Care positions in Q1 2022 and 66 closed out, a net change of -4 holders.
- The largest Tandem Diabetes Care buyer in Q1 2022 was Fidelity Investments, an estimated $58M added.
- The largest Tandem Diabetes Care seller in Q1 2022 was Jackson Square Partners, an estimated $117M sold.
Based on aggregated 13F filings for Q1 2022.